<DOC>
	<DOCNO>NCT02060721</DOCNO>
	<brief_summary>Long-term study evaluate macitentan safe , tolerable efficient enough use treatment inoperable chronic thromboembolic pulmonary hypertension ( CTEPH )</brief_summary>
	<brief_title>Clinical Study Assess Safety , Tolerability Efficacy Macitentan Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Written inform consent Subject CTEPH complete doubleblind ( DB ) AC055E201/ MERIT1 study schedule ( i.e. , remain DB study Week 24 ) . Females childbearing potential must negative pretreatment serum pregnancy test , advise appropriate method contraception , agree use 2 reliable method contraception . Permanent discontinuation DB study treatment due hepatic adverse event liver aminotransferase abnormality . Any known factor ( e.g. , drug substance abuse ) disease ( e.g. , unstable psychiatric illness ) , opinion investigator , may interfere treatment compliance interpretation result , may influence ability comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Chronic thromboembolic pulmonary hypertension ( CTEPH )</keyword>
</DOC>